Ghrelin suppression is associated with weight loss and insulin action following gastric bypass surgery at 12 months in obese adults with type 2 diabetes. Academic Article uri icon

Overview

abstract

  • Roux-en-Y gastric bypass (RYGB) surgery reverses type 2 diabetes mellitus (T2DM) in approximately 80% of patients. Ghrelin regulates glucose homeostasis, but its role in T2DM remission after RYGB surgery is unclear. Nine obese T2DM subjects underwent a mixed meal tolerance test before and at 1 and 12 months after RYGB surgery. Changes in ghrelin, body weight, glucagon-like polypeptide-1 (GLP-1, glucose tolerance and insulin sensitivity (IS) were measured. At 1 month, body weight, glycaemia and IS were improved, while ghrelin concentrations were reduced (p < 0.05). After 12 months, body weight and fasting glucose were reduced (30 and 16%, respectively; p < 0.05) and IS was enhanced (threefold; p < 0.05). Ghrelin suppression improved by 32% at 12 months (p < 0.05), and this was associated with weight loss (r = 0.72, p = 0.03), enhanced IS (r = -0.78, p = 0.01) and peak postprandial GLP-1 (r = -0.73, p = 0.03). These data suggest that postprandial ghrelin suppression may be part of the mechanism that contributes to diabetes remission after RYGB surgery.

publication date

  • May 21, 2013

Research

keywords

  • Diabetes Mellitus, Type 2
  • Gastric Bypass
  • Ghrelin
  • Insulin
  • Insulin Resistance
  • Obesity, Morbid
  • Remission Induction
  • Weight Loss

Identity

PubMed Central ID

  • PMC5214997

Scopus Document Identifier

  • 84883741644

Digital Object Identifier (DOI)

  • 10.1111/dom.12118

PubMed ID

  • 23679188

Additional Document Info

volume

  • 15

issue

  • 10